SynAct Pharma (OM:SYNACT) - Stock Price, News & Analysis

SYNACT Stock Overview

A clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. More details

SYNACT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue (SEK0)

Earnings have declined by 42.9% per year over past 5 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap (SEK385M)

+ 1 more risk

SynAct Pharma AB Competitors

Initiator Pharma

OM:INIT

SEK 362.8m

Mendus

OM:IMMU

SEK 418.9m

Lipum

OM:LIPUM

SEK 354.2m

Curasight

NGM:CURAS

DKK 225.4m

Price History & Performance

Summary of all time highs, changes and price drops for SynAct Pharma
Historical stock prices
Current Share Price	SEK 9.33
52 Week High	SEK 13.80
52 Week Low	SEK 4.98
Beta	0.65
11 Month Change	4.13%
3 Month Change	12.82%
1 Year Change	41.15%
33 Year Change	-92.92%
5 Year Change	-5.76%
Change since IPO	79.42%

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Sep 18

Recent updates

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

Shareholder Returns

	SYNACT	SE Biotechs	SE Market
7D	8.5%	-0.4%	0.1%
1Y	41.1%	15.1%	11.8%

Return vs Industry: SYNACT exceeded the Swedish Biotechs industry which returned 15.1% over the past year.

Return vs Market: SYNACT exceeded the Swedish Market which returned 11.8% over the past year.

Price Volatility

Is SYNACT's price volatile compared to industry and market?
SYNACT volatility
SYNACT Average Weekly Movement	9.5%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: SYNACT's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: SYNACT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2012	5	Jeppe Ovlesen	synactpharma.com

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.

SynAct Pharma AB Fundamentals Summary

How do SynAct Pharma's earnings and revenue compare to its market cap?
SYNACT fundamental statistics
Market cap	SEK 385.30m
Earnings (TTM)	-SEK 154.57m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.5x

P/E Ratio

Is SYNACT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYNACT income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 154.57m
Earnings	-SEK 154.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 18, 2025

Earnings per share (EPS)	-3.74
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SYNACT perform over the long term?

See historical performance and comparison

SYNACT Stock Overview

Risk Analysis

SynAct Pharma AB Competitors

OM:INIT

SEK 362.8m

OM:IMMU

SEK 418.9m

OM:LIPUM

SEK 354.2m

NGM:CURAS

DKK 225.4m

Price History & Performance

Recent News & Updates

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 44.902176 million.

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Recent updates

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 44.902176 million.

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Chief Operating Officer recently bought kr1.9m worth of stock

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis